With the consummation of the merger, Targanta has become a wholly owned subsidiary of The Medicines Company.
Clive Meanwell, chairman and CEO of The Medicines Company, said: “This completes another step in our strategy to build a leading, global critical care medicines business. We now look forward to design and implementation of an oritavancin Phase III clinical trial program.”